WTX 231
Alternative Names: WTX-231Latest Information Update: 06 Aug 2022
At a glance
- Originator Westlake Therapeutics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Jul 2022 Westlake therapeutics intends to apply for clinical trial ethics approval for WTX 231 (Westlake therapeutics pipeline; July 2022)
- 21 Jul 2022 Westlake Therapeutics has patent protection for the development of red blood cell therapy technology (Westlake Therapeutics website; July 2022)
- 21 Jul 2022 Preclinical trials in Cancer in China (Parenteral) (Westlake therapeutics pipeline, July 2022)